PFK15, a small molecule inhibitor of PFKFB3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Zhu, Wei ^a   Ye, Liang ^b,c   Zhang, Jianzhao ^b   Yu, Pengfei ^b   Wang, Hongbo ^d   Ye, Zuguang ^a   Tian, Jingwei ^b,d  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Luye Pharma Group Ltd   (China)

^c BINZHOU MEDICAL UNIVERSITY   (China)

^d YANTAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 PYRIDINYL) 3 (2 QUINOLINYL) 2 PROPEN 1 ONE; 6 PHOSPHOFRUCTO 2 KINASE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; CYCLIN E1; FOCAL ADHESION KINASE; P CADHERIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR INVASION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

EID: 84992437322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0163768     Document Type: Article

References (39)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64 (1):9-29. doi: 10.3322/caac.21208
2. Suzuki R, Yamamoto E, Nojima M, Maruyama R, Yamano HO, Yoshikawa K et al. Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. Journal of gastroenterology. 2014; 49(7):1135-44. doi: 10.1007/s00535-013-0861-7 PMID: 23942619
3. Cravo M, Fidalgo C, Garrido R, Rodrigues T, Luz G, Palmela C et al. Towards curative therapy in gastric cancer: Faraway, so close! World journal of gastroenterology. 2015; 21(41):11609-20. doi: 10.3748/wjg.v21.i41.11609 PMID: 26556990
4. Satolli MA, Buffoni L, Spadi R, Roato I. Gastric cancer: The times they are a-changin'. World journal of gastrointestinal oncology. 2015; 7(11):303-16. doi: 10.4251/wjgo.v7.i11.303 PMID: 26600930
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
6. Warburg O. On the origin of cancer cells. Science (New York, NY). 1956; 123(3191):309-14.
7. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer research. 2002; 62(20):5881-7. PMID: 12384552
8. Minchenko OH, Tsuchihara K, Minchenko DO, Bikfalvi A, Esumi H. Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells. World journal of gastroenterology. 2014; 20 (38):13705-17. doi: 10.3748/wjg.v20.i38.13705 PMID: 25320508
9. Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell. 2012; 149(1):49-62. doi: 10.1016/j.cell. 2012.02.030 PMID: 22401813
10. Ge X, Lyu P, Gu Y, Li L, Li J, Wang Y et al. Sonic hedgehog stimulates glycolysis and proliferation of breast cancer cells: Modulation of PFKFB3 activation. Biochemical and biophysical research communications. 2015; 464(3):862-8. doi: 10.1016/j.bbrc.2015.07.052 PMID: 26171876
11. Huang LE. Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell death and differentiation. 2008; 15(4):672-7. doi: 10.1038/sj.cdd.4402302 PMID: 18188166
12. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Molecular cancer therapeutics. 2008; 7(1):110-20. doi: 10.1158/1535-7163.mct-07-0482 PMID: 18202014
13. Seo M, Kim JD, Neau D, Sehgal I, Lee YH. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PloS one. 2011; 6(9):e24179. doi: 10.1371/journal.pone.0024179 PMID: 21957443
14. Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Molecular cancer therapeutics. 2013; 12(8):1461-70. doi: 10.1158/1535-7163.MCT-13-0097 PMID: 23674815
15. Wang W, Wang H, Ni Y, Yao Z, Ye L, Tian J. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016. doi: 10.1007/s13277-016-4826-3
16. Huang C, Wu J, Liao R, Zhang W. SKF83959, an agonist of phosphatidylinositol-linked D(1)-like receptors, promotes ERK1/2 activation and cell migration in cultured rat astrocytes. PloS one. 2012; 7(11): e49954. doi: 10.1371/journal.pone.0049954 PMID: 23185493
17. Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell death & disease. 2014; 5:e1337. doi: 10.1038/cddis.2014.292
18. Schaftingen E, Lederer B, Bartrons R, Hers H-G. A Kinetic Study of Pyrophosphate: Fructose-6-Phosphate Phosphotransferase from Potato Tubers. Application to a Microassay of Fructose 2,6-Bisphosphate. European Journal of Biochemistry. 1982; 129(1):191-5.
19. Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL et al. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. The Journal of biological chemistry. 2009; 284(36):24223-32. doi: 10.1074/jbc.M109.016816 PMID: 19473963
20. Xu Y, An X, Guo X, Habtetsion TG, Wang Y, Xu X et al. Endothelial PFKFB3 plays a critical role in angiogenesis. Arteriosclerosis, thrombosis, and vascular biology. 2014; 34(6):1231-9. doi: 10.1161/atvbaha.113.303041 PMID: 24700124
21. Sherr CJ. Cancer cell cycles. Science (New York, NY). 1996; 274(5293):1672-7.
22. Wang JB, Qi LL, Zheng SD, Wu TX. Curcumin induces apoptosis through the mitochondria-mediated apoptotic pathway in HT-29 cells. Journal of Zhejiang University Science B. 2009; 10(2):93-102. doi: 10.1631/jzus.B0820238 PMID: 19235267
23. Ma L, Li W. Emodin inhibits LOVO colorectal cancer cell proliferation via the regulation of the Bcl-2/Bax ratio and cytochrome. Experimental and therapeutic medicine. 2014; 8(4):1225-8. doi: 10.3892/etm. 2014.1900 PMID: 25187829
24. Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW. Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. British journal of cancer. 2002; 87(5):555-61. doi: 10.1038/sj.bjc.6600496 PMID: 12189556
25. Venning FA, Wullkopf L, Erler JT. Targeting ECM Disrupts Cancer Progression. Frontiers in oncology. 2015; 5:224.
26. Sottnik JL, Lori JC, Rose BJ, Thamm DH. Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clinical & experimental metastasis. 2011; 28(8):865-75. doi: 10.1007/s10585-011-9417-5
27. Du JY, Wang LF, Wang Q, Yu LD. miR-26b inhibits proliferation, migration, invasion and apoptosis induction via the downregulation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 driven glycolysis in osteosarcoma cells. Oncology reports. 2015; 33(4):1890-8. doi: 10.3892/or.2015.3797 PMID: 25672572
28. Dittmar Y, Settmacher U. Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World journal of gastrointestinal oncology. 2015; 7(11):292-302. doi: 10.4251/wjgo.v7.i11.292 PMID: 26600929
29. Davidson M, Okines AF, Starling N. Current and Future Therapies for Advanced Gastric Cancer. Clinical colorectal cancer. 2015; 14(4):239-50. doi: 10.1016/j.clcc.2015.05.013 PMID: 26524924
30. Coghlin C, Murray GI. Progress in the development of protein biomarkers of oesophageal and gastric cancers. Proteomics Clinical applications. 2015. doi: 10.1002/prca.201500079
31. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006; 25(38):5220-7. doi: 10.1038/sj.onc.1209615 PMID: 16936740
32. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Molecular and cellular biology. 1998; 18 (2):753-61. PMID: 9447971
33. Duronio RJ, O'Farrell PH, Xie JE, Brook A, Dyson N. The transcription factor E2F is required for S phase during Drosophila embryogenesis. Genes & development. 1995; 9(12):1445-55.
34. Niu Z, Liu H, Zhou M, Wang H, Liu Y, Li X et al. Knockdown of c-Myc inhibits cell proliferation by negatively regulating the Cdk/Rb/E2F pathway in nasopharyngeal carcinoma cells. Acta biochimica et biophysica Sinica. 2015; 47(3):183-91.
35. Shibue T, Brooks MW, Inan MF, Reinhardt F, Weinberg RA. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer discovery. 2012; 2(8):706-21.
36. Li XY, Zhou X, Rowe RG, Hu Y, Schlaepfer DD, Ilic D et al. Snail1 controls epithelial-mesenchymal lineage commitment in focal adhesion kinase-null embryonic cells. The Journal of cell biology. 2011; 195(5):729-38.
37. Canel M, Serrels A, Frame MC, Brunton VG. E-cadherin-integrin crosstalk in cancer invasion and metastasis. Journal of cell science. 2013; 126(Pt 2):393-401.
38. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell. 2001; 105(3):391-402. PMID: 11348595
39. Medrek C, Landberg G, Andersson T, Leandersson K. Wnt-5a-CKI{alpha} signaling promotes {beta}-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. The Journal of biological chemistry. 2009; 284(16):10968-79.